A randomized phase III trial found that another SNP rs1693482 in ADH1C significantly affected OS in breast cancer patients undergoing neoadjuvant chemotherapy and without the need to achieve PCR (Le Morvan et al., 2015). Here, ADH1C is linked to breast carcinoma.